Institution
University of Naples Federico II
Education•Naples, Campania, Italy•
About: University of Naples Federico II is a education organization based out in Naples, Campania, Italy. It is known for research contribution in the topics: Population & Cancer. The organization has 29291 authors who have published 68803 publications receiving 1920149 citations. The organization is also known as: Università degli Studi di Napoli Federico II & Naples University.
Topics: Population, Cancer, Large Hadron Collider, European Prospective Investigation into Cancer and Nutrition, Blood pressure
Papers published on a yearly basis
Papers
More filters
••
French Institute of Health and Medical Research1, Institut Gustave Roussy2, University of Naples Federico II3, University of Paris-Sud4, University of Rome Tor Vergata5, Boston Children's Hospital6, Centre national de la recherche scientifique7, University of Gothenburg8, Foundation for Research & Technology – Hellas9, University of Ferrara10, Stony Brook University11, University of Graz12, University College London13
TL;DR: Evidence is provided of a key signalling pathway that links autophagy to the cancer-associated dysregulation of p53, which improved the survival of p 53-deficient cancer cells under conditions of hypoxia and nutrient depletion, allowing them to maintain high ATP levels.
Abstract: Multiple cellular stressors, including activation of the tumour suppressor p53, can stimulate autophagy. Here we show that deletion, depletion or inhibition of p53 can induce autophagy in human, mouse and nematode cells subjected to knockout, knockdown or pharmacological inhibition of p53. Enhanced autophagy improved the survival of p53-deficient cancer cells under conditions of hypoxia and nutrient depletion, allowing them to maintain high ATP levels. Inhibition of p53 led to autophagy in enucleated cells, and cytoplasmic, not nuclear, p53 was able to repress the enhanced autophagy of p53(-/-) cells. Many different inducers of autophagy (for example, starvation, rapamycin and toxins affecting the endoplasmic reticulum) stimulated proteasome-mediated degradation of p53 through a pathway relying on the E3 ubiquitin ligase HDM2. Inhibition of p53 degradation prevented the activation of autophagy in several cell lines, in response to several distinct stimuli. These results provide evidence of a key signalling pathway that links autophagy to the cancer-associated dysregulation of p53.
1,075 citations
••
TL;DR: In this paper, the past contributions of CIRP in these areas are reviewed and an up-to-date comprehensive survey of sensor technologies, signal processing, and decision making strategies for process monitoring is provided.
1,074 citations
••
King's College London1, University of Nottingham2, University of Naples Federico II3, Royal College of Surgeons in Ireland4, Swansea University5, University of Calgary6, Scripps Research Institute7, University of Melbourne8, University of California, San Diego9, Nanjing Medical University10, University of Liverpool11, La Trobe University12, University College London13, Universidade Federal de Minas Gerais14, University of Bath15, Queen Mary University of London16
TL;DR: The guidelines have been simplified for ease of understanding by authors, to make it more straightforward for peer reviewers to check compliance and to facilitate the curation of the journal's efforts to improve standards.
Abstract: This article updates the guidance published in 2015 for authors submitting papers to British Journal of Pharmacology (Curtis et al., 2015) and is intended to provide the rubric for peer review. Thus, it is directed towards authors, reviewers and editors. Explanations for many of the requirements were outlined previously and are not restated here. The new guidelines are intended to replace those published previously. The guidelines have been simplified for ease of understanding by authors, to make it more straightforward for peer reviewers to check compliance and to facilitate the curation of the journal's efforts to improve standards.
1,070 citations
••
University of Glasgow1, Jagiellonian University2, Queen Mary University of London3, Vanderbilt University Medical Center4, University of Manchester5, University of Naples Federico II6, University of Roehampton7, University of Texas at Austin8, Jagiellonian University Medical College9, Humboldt University of Berlin10, Huazhong University of Science and Technology11, Catholic University of the Sacred Heart12
TL;DR: While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis, Hence, patients should not discontinue their use.
Abstract: The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades. We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies. While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system. Risk of severe infection and mortality increase with advancing age and male sex. Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer. The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC). Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) -a homologue of ACE-to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes. This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI). While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis. Hence, patients should not discontinue their use. Moreover, renin-angiotensin-aldosterone system (RAAS) inhibitors might be beneficial in COVID-19. Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19. Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications. Preventive measures (social distancing and social isolation) also increase cardiovascular risk. Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.
1,060 citations
••
TL;DR: Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning are studied.
Abstract: Morosini P-L, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning.
Acta Psychiatr Scand 2000: 101:323–329. © Munksgaard 2000.
Objective: Development of a scale to assess patients' social functioning, the Personal and Social Performance scale (PSP).
Method: PSP has been developed through focus groups and reliability studies on the basis of the social functioning component of the DSM-TV Social and Occupational Functioning Assessment Scale (SOFAS). The last reliability study was carried out by 39 workers with different professional roles on a sample of 61 psychiatric patients admitted to the rehabilitation unit. Each patient was rated independently on the scale by the two workers who knew them best.
Results: The PSP is a 100–point single-item rating scale, subdivided into 10 equal intervals. The ratings are based mainly on the assessment of patient's functioning in four main areas: 1) socially useful activities; 2) personal and social relationships; 3) self-care; and 4) disturbing and aggressive behaviours. Operational criteria to rate the levels of disabilities have been defined for the above-mentioned areas. Excellent inter-rater reliability was also obtained in less educated workers.
Conclusion: Compared to SOFAS, PSP has better face validity and psychometric properties. It was found to be an acceptable, quick and valid measure of patients' personal and social functioning.
1,059 citations
Authors
Showing all 29740 results
Name | H-index | Papers | Citations |
---|---|---|---|
D. M. Strom | 176 | 3167 | 194314 |
Yang Gao | 168 | 2047 | 146301 |
Robert Stone | 160 | 1756 | 167901 |
Elio Riboli | 158 | 1136 | 110499 |
Barry J. Maron | 155 | 792 | 91595 |
H. Eugene Stanley | 154 | 1190 | 122321 |
Paul Elliott | 153 | 773 | 103839 |
Robert O. Bonow | 149 | 808 | 114836 |
Kai Simons | 147 | 426 | 93178 |
Peter Buchholz | 143 | 1181 | 92101 |
Martino Margoni | 141 | 2059 | 107829 |
H. A. Neal | 141 | 1903 | 115480 |
Luca Lista | 140 | 2044 | 110645 |
Pierluigi Paolucci | 138 | 1965 | 105050 |
Ari Helenius | 137 | 298 | 64789 |